- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Melanoma | Clinical
Study of UV1 Plus Nivolumab/Ipilimumab Completes Enrollment of Patients With Melanoma
July 07, 2022
The recruitment of patients with melanoma has been completed in the phase 2 INITIUM clinical trial. Topline results from the study are expected to be reported in early 2023.
Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma
June 05, 2022
Adjuvant pembrolizumab improved distant metastasis-free survival and longer follow up for recurrence-free survival in patients with resected stage IIB or stage IIC melanoma, according to data discussed at the 2022 ASCO Annual Meeting.
A Decade of Transformation in Melanoma Treatments
May 23, 2022
Ongoing and proposed melanoma research will naturally continue to evaluate new treatment types.
Study of ATL001 Plus ICI Therapy Now Enrolling Patients with Metastatic Melanoma
May 09, 2022
The phase 1/2 THETIS clinical trial is actively recruiting patients with metastatic melanoma to be treated with the investigation combination of ATL001 and an immune checkpoint inhibitor.
Spartalizumab With Dabrafenib and Trametinib Shows Modest Efficacy in BRAF V600+ Metastatic Melanoma
May 05, 2022
The phase 3 COMBI-i trial demonstrated that spartalizumab plus dabrafenib and trametinib has modest efficacy in BRAF V600-positive metastatic melanoma, but no progression-free survival benefit when compared with dabrafenib and trametinib alone.
Melanoma Monday: A Review of the MSLT-II Trial and Completion Lymph Node Dissection
May 02, 2022
Katherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.
FDA Grants Orphan Drug Designation to Darovasertib for Uveal Melanoma Treatment
May 02, 2022
With an FDA orphan drug designation for the treatment of patients with uveal melanoma, darovasertib is being actively investigated in a phase 1/2 clinical trial.
MATINS Trial Results Will Be Shared at EADO
April 28, 2022
Results from the melanoma cohort the MATINS trial will be shared at the 18th Congress of the European Association of Dermato-Oncology.
Combo of BO-112 and Pembrolizumab Elicits Response in Advanced Melanoma
April 21, 2022
For advanced melanoma that is resistant to anti–PD-1 therapies, the addition of BO-112 to pembrolizumab appears to be effective and safe.
Delays in BRAF Test Results Affect Quality of Care, Therapeutic Options in Melanoma
April 13, 2022
Barriers to improving BRAF testing turnaround time in patients with melanoma have been identified in a retrospective analysis of real-world data collected in Canada.